BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

Nike revenue falls 4 percent as Greater China and direct sales weaken; company cuts fiscal 2027 outlook to high-single-digit decline

Moe Alsumidaie by Moe Alsumidaie
October 2, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Nike’s first quarter revenue dropped 4 percent to $11.2 billion, driven by declines in Greater China and a 13 percent plunge in digital sales, even as the company expanded gross margin by 60 basis points through lower logistics costs. The company cut its fiscal 2027 revenue outlook to a high-single-digit decline, signaling that weakness in key markets persists beyond the quarter just reported.

Nike Brand revenue fell 4 percent on a currency-neutral basis to $11.0 billion. Within that, wholesale held relatively steady, down 1 percent, but Nike Direct collapsed 9 percent currency-neutral, with digital sales down 13 percent and owned stores down 5 percent. Converse, the subsidiary brand, fell 28 percent across all territories. Gross margin improved to 42.8 percent from 42.2 percent a year earlier, primarily from lower warehousing and logistics costs. Diluted earnings per share came in at $0.48, down from $0.49 in the prior year quarter, as a higher tax rate offset the margin gain. For fiscal 2027, Nike guided adjusted diluted earnings per share to a range of $1.15 to $1.35, excluding approximately $0.15 of restructuring charges tied to the company’s new Pace operating model.

What it means

The margin expansion masks a revenue problem that Nike’s own guidance now confirms will worsen. The 60 basis point gross margin gain came entirely from supply chain efficiency, not from pricing power or product mix; cost of sales fell 5 percent while revenues fell only 4 percent. That tailwind is unlikely to repeat if revenue declines accelerate. The company’s guidance for high-single-digit revenue decline in fiscal 2027 suggests management expects conditions to deteriorate from the 4 percent drop in Q1, a signal that the current quarter’s results do not represent stabilization.

The digital sales collapse, down 13 percent, is the most concrete warning sign. Nike Direct, which the company has positioned as a strategic priority, is contracting faster than wholesale. Greater China weakness persists despite the company’s stated focus on that market. The Pace restructuring program, which Nike expects to deliver $2.5 billion in cumulative savings through fiscal 2031, includes a supply chain modernization and a new India campus, but the company will take $0.3 billion in severance charges in fiscal 2026 and another $0.3 billion in fiscal 2027. Those charges are excluded from the adjusted earnings guidance, meaning reported earnings will be pressured in the near term.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: NIKE, Inc. and 500+ other names, on the same official data.See the evidence engine →

The honest open question is whether the Sport Offense strategy, the company’s focus on performance-driven athletic products, can offset the drag from Sportswear and Jordan Brand repositioning. Nike’s commentary emphasizes that Sport Offense is “driving measurable progress,” but the filing does not quantify that progress or show which sport categories are growing. The company also does not disclose whether the digital decline reflects traffic loss, conversion loss, or both, leaving unclear whether the problem is demand or execution.

What to watch

Nike’s next quarterly report, due in January 2027 for Q2 fiscal 2027, will show whether the high-single-digit revenue decline guidance is tracking or whether the company needs to cut further. That filing will also reveal the early impact of Pace and whether the restructuring is disrupting operations or stabilizing the business. Any material miss on the $1.15 to $1.35 adjusted earnings range would signal that cost savings are not materializing as planned.

Source: the company’s 8-K filed 2026-10-01 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.

For the standing yardsticks on Nike: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Nike.

BullScope TerminalYou just read NIKE, Inc.’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Zoetis narrows revenue outlook as U.S. companion animal sales slide, raises profit guidance on margin strength

by Moe Alsumidaie
November 6, 2026
0

Zoetis cut its full-year revenue forecast to $9.220 billion to $9.320 billion, representing organic operational decline of 2 percent to 1 p

Read moreDetails

Viatris Raises 2026 Guidance as Adjusted EBITDA Climbs 9 Percent Year to Date

by Moe Alsumidaie
November 6, 2026
0

Viatris raised the midpoints of its full-year 2026 financial guidance across all key metrics on the strength of nine-month adjusted EBITDA

Read moreDetails

Joby Aviation raises FY26 revenue outlook 15% as eIPP flights and defense contracts accelerate path to certification

by Moe Alsumidaie
November 5, 2026
0

Joby Aviation lifted its full-year 2026 revenue guidance by 15 percent and completed the first crewed eVTOL flights under the federal gover

Read moreDetails

Amgen’s revenue growth slows to 8% as biosimilar competition erodes legacy franchises

by Moe Alsumidaie
November 4, 2026
0

Amgen's third-quarter revenue rose 8% to $10.4 billion, a deceleration from the 10.0% full-year growth rate filed for fiscal 2025. The slow

Read moreDetails

Palantir’s U.S. commercial revenue overtakes government for the first time as quarterly sales accelerate to 96% growth

by Moe Alsumidaie
November 3, 2026
0

Palantir Technologies raised full-year revenue guidance to 91% growth after U.S. commercial revenue surpassed U.S. government revenue in th

Read moreDetails
Next Post

Supernus: Revenue Up 32%, Earnings Negative. One Quarter Holds Both Facts.

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

NVIDIA at the cheap end of its own decade: when the math outgrows the mood

NVIDIA at the cheap end of its own decade: when the math outgrows the mood

July 30, 2026

Hiring Slowed, Prices Cooled, and the Fed Held Steady: What June’s Numbers Mean for Earnings Season

August 18, 2026

Half the Price, Same Business: What Zoetis’s Filed Numbers Actually Say

August 31, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.